Jushi Holdings Inc. Virtual 2020 Investor and Analyst Day Replay Now Available

 Jushi Holdings Inc. , a globally focused, multi-state cannabis and hemp operator, announced that a replay of the Company’s virtual investor and analyst day event held on October 1, 2020 is now available. The virtual event included presentations by James (“Jim”) Cacioppo, Chief Executive Officer, Chairman and Founder, Erich Mauff, President, Board Member and Founder, Jon Barack, President and Founder, and Kimberly Bambach, Chief Financial Officer. In addition, members of Jushi’s extended senior leadership team provided updates on each of the Company’s operating divisions.

Virtual Investor Day and Replay Details

The replay of Jushi’s first investor day will be available on demand on the Company’s Investor Relations website until 12:00 midnight Eastern Time Thursday, September 30, 2021. 

Updated Guidance

Prior to this event, Jushi provided updated preliminary financial guidance for its third quarter ending September 20, 2020 (“Q3 2020”) as well as updated guidance for its fourth quarter ended December 31, 2020, (“Q4 2020”) and fiscal year 2021. The Company reported that it anticipates the following:

• Q3 2020 estimated revenue of at least $24 million, representing 61% sequential growth;
• Q4 2020 total revenue to be at the high end of $25-30 million and to report positive adjusted EBITDA¹;
• Total fiscal year 2021 revenue expected to be between $205-255 million; adjusted EBITDA¹ is expected to be between $40-50 million;
• On a geographic basis, fiscal year 2021 total revenue is expected to break down in each state where Jushi is currently active as follows:         
  • Pennsylvania: $95 – 110 million
  • Illinois: $70 – 80 million
  • Virginia: $17 – 25 million
  • California: $12 – 20 million
  • Nevada: $5.5 – 10 million
  • Ohio: $5.5 – 10 million
• Operating cash flow positive in fiscal year 2021

Jushi also confirmed that as of August 31, 2020, the Company had an estimated $44 million of cash, as well as $7.5 million in marketable securities.

¹ Adjusted EBITDA is a non-IFRS financial measure. See Non-IFRS Measures Section of this news release. Please refer to, “Reconciliation of Non-IFRS Measures” of the Company’s Q2 MD&A for adjusted EBITDA calculations.  

About Jushi Holdings Inc.
We are a globally focused cannabis and hemp company led by an industry leading management team. In the United States Jushi is focused on building a multi-state portfolio of branded cannabis and hemp-derived assets through opportunistic acquisitions, distressed workouts, and competitive applications. Jushi strives to maximize shareholder value while delivering high quality products across all levels of the cannabis and hemp ecosystem. For more information please visit www.jushico.com or our social media channels, Instagram, Facebook, Twitter, and LinkedIn.

Non-IFRS Financial Measures

We define EBITDA as net income (loss), or “earnings”, before interest, income taxes, depreciation, and amortization. We define Adjusted EBITDA as EBITDA before: (i) fair value adjustments on biological assets and fair value adjustments on sale of inventory; (ii) share-based compensation expense; (iii) fair value changes in derivative warrants; (iv) net gain on business combination; (v) gains and losses on investments and financial assets; and (vi) pre-acquisition expense.

Adjusted EBITDA is not a recognized performance measure under IFRS, does not have a standardized meaning and therefore may not be comparable to similar measures presented by other issuers. Adjusted EBITDA is included as a supplemental disclosure because we believe that such measurement provides a better assessment of the Company’s operations on a continuing basis by eliminating certain material non-cash items and certain other adjustments we believe are not reflective of the Company’s ongoing operations and performance. Adjusted EBITDA has limitations as an analytical tool as it excludes from net income as reported interest, tax, depreciation, non-cash expenses, RTO expense, other income, grow cost expensed for biological assets and unsold inventory, and the non-cash fair value effects of accounting for biological assets and inventories. Because of these limitations, Adjusted EBITDA should not be considered as the sole measure of the Company’s performance and should not be considered in isolation from, or as a substitute for, analysis of the Company’s results as reported under IFRS. The most directly comparable measure to Adjusted EBITDA calculated in accordance with IFRS is operating income (loss).

For further information, please contact:

Investor Relations
Michael Perlman
Executive Vice President of Investor Relations and Treasury
Investors@jushico.com
(561) 453-1308

Media Contact
Ellen Mellody
MATTIO Communications
Ellen@Mattio.com
(570) 209-2947